ATE327229T1 - Verbindungen und deren verwendung als 5-ht inhibitore - Google Patents

Verbindungen und deren verwendung als 5-ht inhibitore

Info

Publication number
ATE327229T1
ATE327229T1 AT03725958T AT03725958T ATE327229T1 AT E327229 T1 ATE327229 T1 AT E327229T1 AT 03725958 T AT03725958 T AT 03725958T AT 03725958 T AT03725958 T AT 03725958T AT E327229 T1 ATE327229 T1 AT E327229T1
Authority
AT
Austria
Prior art keywords
sup
compounds
inhibiters
preparation
medicament
Prior art date
Application number
AT03725958T
Other languages
English (en)
Inventor
Bjoern Nilsson
Erik Ringberg
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Application granted granted Critical
Publication of ATE327229T1 publication Critical patent/ATE327229T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
AT03725958T 2002-05-17 2003-05-16 Verbindungen und deren verwendung als 5-ht inhibitore ATE327229T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201544A SE0201544D0 (sv) 2002-05-17 2002-05-17 Novel compounds and thier use
US41003802P 2002-09-12 2002-09-12

Publications (1)

Publication Number Publication Date
ATE327229T1 true ATE327229T1 (de) 2006-06-15

Family

ID=29552452

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03725958T ATE327229T1 (de) 2002-05-17 2003-05-16 Verbindungen und deren verwendung als 5-ht inhibitore

Country Status (24)

Country Link
US (1) US7229997B2 (de)
EP (1) EP1506185B1 (de)
JP (1) JP4865221B2 (de)
KR (1) KR20050026702A (de)
CN (1) CN1329389C (de)
AT (1) ATE327229T1 (de)
AU (1) AU2003228196B2 (de)
BR (1) BR0310077A (de)
CA (1) CA2483619A1 (de)
CY (1) CY1105162T1 (de)
DE (1) DE60305484T2 (de)
DK (1) DK1506185T3 (de)
EA (1) EA007543B1 (de)
ES (1) ES2263971T3 (de)
IL (1) IL164974A0 (de)
MX (1) MXPA04011437A (de)
NO (1) NO20045486L (de)
NZ (1) NZ536409A (de)
PT (1) PT1506185E (de)
RS (1) RS99804A (de)
SE (1) SE0201544D0 (de)
SI (1) SI1506185T1 (de)
WO (1) WO2003097636A1 (de)
ZA (1) ZA200408975B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
EP1792629A4 (de) 2004-08-25 2010-08-25 Takeda Pharmaceutical Mittel zur prävention/behandlung von stressbedingter harninkontinenz und vorsorgeuntersuchungsverfahren dafür
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
EP2386554A1 (de) 2005-07-04 2011-11-16 High Point Pharmaceuticals, LLC Histamine H3 Rezeptor aktive Verbindungen
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
PA8720901A1 (es) * 2006-03-24 2008-11-19 Wyeth Corp Tratamiento del dolor
CN101410112A (zh) * 2006-03-24 2009-04-15 惠氏公司 治疗抑郁症的新治疗组合
EP2727585A1 (de) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo Screening-Methode
EP2079732B9 (de) * 2006-05-29 2012-03-21 High Point Pharmaceuticals, LLC 3-(1,3-benyodioxol-5-yl)-6- (4-cyclopropylpiperazin-1-yl)-pyridazin, dessen salze und solvate und dessen verwendung als histamin-h3-rezeptorantagonist
US20070293475A1 (en) * 2006-06-20 2007-12-20 Alcon Manufacturing Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
TW200823187A (en) * 2006-10-24 2008-06-01 Wyeth Corp Benzodioxane derivatives and uses thereof
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JP5431305B2 (ja) 2007-04-23 2014-03-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 高速解離性ドパミン２受容体アンタゴニストとしての４−アルコキシピリダジン誘導体
WO2008128996A1 (en) 2007-04-23 2008-10-30 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
EP2014656A3 (de) * 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC Neue heterocyclische H3-Antagonisten
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
EP2216023A4 (de) 2007-11-15 2013-03-13 Takeda Pharmaceutical Kondensiertes pyridinderivat und seine verwendung
EP2310374B1 (de) 2008-07-03 2012-10-31 Janssen Pharmaceutica N.V. Substituierte 6-(1-piperazinyl)pyridazine als antagonisten am 5-ht6-rezeptor
EP2307374B1 (de) * 2008-07-31 2017-01-25 Janssen Pharmaceutica NV Piperazin-1-yl-trifluoromethyl-substituierte-pyridine als schnell dissoziierende dopamin 2-rezeptorantagonisten
JP5579262B2 (ja) 2009-06-15 2014-08-27 武田薬品工業株式会社 ピラジノオキサゼピン誘導体
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
TWI589576B (zh) 2011-07-15 2017-07-01 諾華公司 氮雜－雙環二芳基醚之鹽類及製造彼等或其前驅物之方法
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
TW202504600A (zh) * 2023-07-04 2025-02-01 大陸商杭州中美華東製藥有限公司 Glp1r激動劑及其中間體的製備方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4078063A (en) * 1976-09-24 1978-03-07 Merck & Co., Inc. Piperazinylpyridines
EP0370560B1 (de) * 1988-11-24 1994-01-12 Akzo Nobel N.V. 1-[Mono- oder bis(trifluormethyl)-2-pyridinyl]piperazine enthaltende pharmazeutische Zusammensetzungen
EP0580465A1 (de) * 1992-06-25 1994-01-26 Sanofi Neue therapeutische Verwendung von heterocyclischen Piperazinen als 5-HT3-Agonisten und neue Derivaten
JPH0665203A (ja) * 1992-06-25 1994-03-08 Elf Sanofi ピペラジンのヘテロ環誘導体
SE9202265D0 (sv) * 1992-07-31 1992-07-31 Kabi Pharmacia Ab Novel- pyridyl and pyrimidylpiperazine derivatives
JPH0797370A (ja) * 1993-09-29 1995-04-11 Asahi Chem Ind Co Ltd ２−アルコキシピラジン誘導体およびその用途
WO1998033504A1 (en) * 1997-02-03 1998-08-06 Akzo Nobel N.V. Treatment of urinary incontinence
JP3989102B2 (ja) * 1997-10-02 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリジン誘導体
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
NZ525700A (en) * 2000-11-20 2004-12-24 Biovitrum Ab Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5HT-2 receptor
EP1213017A3 (de) * 2000-12-05 2003-11-12 Akzo Nobel N.V. Verwendung von einem 5-HT2C Rezeptor Agonist zur Behandlung von Hitzewallungen
US6498184B2 (en) * 2000-12-05 2002-12-24 Akzo Nobel N.V. Serotonergic compound for a method of treatment of hot flushes in post-menopausal women

Also Published As

Publication number Publication date
EP1506185A1 (de) 2005-02-16
ZA200408975B (en) 2005-11-14
IL164974A0 (en) 2005-12-18
CN1329389C (zh) 2007-08-01
NO20045486L (no) 2005-02-02
CN1701068A (zh) 2005-11-23
RS99804A (sr) 2006-12-15
DE60305484T2 (de) 2006-11-09
JP2005529926A (ja) 2005-10-06
AU2003228196B2 (en) 2009-12-17
AU2003228196A1 (en) 2003-12-02
EA007543B1 (ru) 2006-10-27
JP4865221B2 (ja) 2012-02-01
US20030232814A1 (en) 2003-12-18
ES2263971T3 (es) 2006-12-16
DK1506185T3 (da) 2006-10-02
EA200401526A1 (ru) 2005-04-28
EP1506185B1 (de) 2006-05-24
BR0310077A (pt) 2005-02-22
CA2483619A1 (en) 2003-11-27
NZ536409A (en) 2007-11-30
MXPA04011437A (es) 2005-02-17
KR20050026702A (ko) 2005-03-15
SE0201544D0 (sv) 2002-05-17
PT1506185E (pt) 2006-10-31
DE60305484D1 (de) 2006-06-29
CY1105162T1 (el) 2010-03-03
WO2003097636A1 (en) 2003-11-27
HK1084941A1 (en) 2006-08-11
SI1506185T1 (sl) 2006-10-31
US7229997B2 (en) 2007-06-12

Similar Documents

Publication Publication Date Title
DE60305484D1 (de) Verbindungen und deren verwendung als 5-ht inhibitore
NO20026064D0 (no) Nye forbindelser
ATE433447T1 (de) Pyrimiidinverbindungen
MY137535A (en) New pyrrolidinium derivatives
SE0302760D0 (sv) New compounds
SE0302139D0 (sv) Novel compounds
SE0300480D0 (sv) Novel compounds
SE0401970D0 (sv) Novel compounds
DE50310161D1 (de) Kationisch substituierte diphenylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
NO20020282L (no) Nytt difenyl-piperidinderivat
TW200738658A (en) Novel compounds
TW200604197A (en) New compounds
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
DE60301339D1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
DE602004031410D1 (de) Inden derivate als pharmazeutika
DE60201259D1 (de) Chemische verbindungen
SE0101038D0 (sv) Novel compounds
DE60208694D1 (de) Piperidinylmorpholinylderivate als modulatoren der aktivität des chemokinrezeptors
SE0303280D0 (sv) Novel compounds
MXPA04005313A (es) Derivados de aminotetralin como antagonistas del receptor muscarinico.
SE9902551D0 (sv) Novel compounds
TW200740781A (en) Novel compounds
NO20060510L (no) Emulgerende systemer inneholdende azetidinderivater
SE0302755D0 (sv) Novel compounds
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1506185

Country of ref document: EP

REN Ceased due to non-payment of the annual fee